No Data
No Data
Agenus Shares Target Cut to $5, Analyst Maintains Buy Rating
On Monday, B.Riley adjusted its outlook on Agenus Inc . (NASDAQ:AGEN), reducing the biotechnology firm's price target to $5 from the previous $6, while still endorsing the stock with a Buy rating.
Agenus Is Maintained at Buy by B. Riley Securities
Agenus Is Maintained at Buy by B. Riley Securities
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating.
US$5.50: That's What Analysts Think Agenus Inc. (NASDAQ:AGEN) Is Worth After Its Latest Results
Little Excitement Around Agenus Inc.'s (NASDAQ:AGEN) Revenues As Shares Take 42% Pounding
Agenus Inc. (NASDAQ:AGEN) shares have had a horrible month, losing 42% after a relatively good period beforehand.
Agenus Inc.'s Future at Risk: Concerns Over Financial Health and Operational Viability
No Data